2020-2027 Analysis and Review Haemophilus Influenzae Type B Vaccines Market

Haemophilus Influenzae Type B Vaccines Market

Haemophilus Influenzae Type B Vaccines Market By Type (Monovalent and Combination), By End Users (Hospitals, Specialty Clinics and Others - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 – 2027

01-06-2020 REP-HC-5103 40 Tables 110 pages Format

The Haemophilus Influenzae Type B vaccines market was valued at USD 1,686.5 Mn by 2019. Rising prevalence of bacterial infection associated with Haemophilus influenza type b bacterium such as meningitis and pneumonia primarily determines the market growth. Furthermore rising public health awareness and effective implementation of the immunization guidelines developed by the World Health Organization (WHO) in consensus with regional government healthcare agencies will further propel the Haemophilus influenza type b vaccines market growth. 

Haemophilus Influenzae Type B Vaccines Market

Haemophilus Influenzae Type B (Hib) bacterium was first discovered during an influenza outbreak in 1892, and further studies elucidated that it is responsible for the occurrence of various invasive diseases such as cellulitis, epiglottitis, meningitis, pneumonia. Hib infections can be treated with antibiotics, but there is a strong probability of developing of resistance to antibiotics, hence immunization at an early age is the most preferred treatment module against the Hib infections.

The major segments related to the Haemophilus Influenzae Type B vaccines market are: 

By Type (2017–2027; US$ Mn)

Monovalent

Combination

By End Users (2017–2027; US$ Mn)

Hospitals

Specialty Clinics

Others

Geography Segment (2017–2027; US$ Mn)

North America

U.S.
Canada

Europe

United Kingdom
Germany
Russia
France
Italy
Spain
Ukraine
Rest of Europe

Asia Pacific

China
Japan
Rest of Asia Pacific

Latin America (LATAM)

Brazil
Mexico
Rest of Latin America

Middle East and Africa (MEA)

GCC
Rest of MEA 

Justification for study?

  • The intention of the study is to give a comprehensive outlook of the global Haemophilus Influenzae Type B vaccines market
  • The overall segmentation of the Haemophilus Influenzae Type B vaccines market, by type, end-users and geography are minutely studied. Monovalent and hospitals are dominating the type and end-user segments respectively
  • Rising prevalence of Haemophilus influenza type b (Hib) infection worldwide
  • Stringent guidelines sanctioned by global healthcare agencies for the compulsory immunization of children with the Haemophilus influenza type b vaccine.

Report gist?

  • The study of the global Haemophilus Influenzae Type B vaccines market includes qualitative analysis of factors such as drivers, restraints, and opportunities
  • The report covers the qualitative and quantitative analysis of the overall market segmented on the basis of type and end-users and categorization of the same at the geography level
  • This research report presents the analysis of each segment from 2017 to 2027 in which 2019 is considered as the base year. The compounded annual growth rate is calculated for the respective segments from 2020 to 2027

The study includes the profiles of major market players with a significant global and regional presence along with top company positioning. 

Significant customers?

  • This study is suitable for industry participants and stakeholders in the pharmaceutical manufacturers actively engaged in the production and marketing of Haemophilus Influenzae Type B vaccines on account of the rising prevalence of the Hib infection worldwide
  • The report will benefit healthcare personnel engaged in the immunization of Haemophilus Influenzae Type B vaccines in children throughout the globe
  • Managers with financial institutions looking to publish recent and forecasted statistics pertaining to Haemophilus Influenzae Type B vaccines market
  • Financial institutions, venture capitalist, analysts, investors, government organizations, policymakers, regulatory authorities, researchers, looking for insights into the market to determine future strategies 

Segment Analysis

In the present scenario, the monovalent is reigning the types segment for the Haemophilus influenza type b vaccines market. It is available as liquid and lyophilized form, it is designed in order to develop immunity against a single strain of antigen of the same microorganism. ActHIB, Hiberix, & PedvaxHIB are highly popular in the developed regions on account of the rising prevalence of meningitis and pneumonia infection among children worldwide. Combination vaccines are expected to register rampant market growth in the near future on account of the cost-effectiveness of the combination of vaccines in the immunization program of children. The most useful application of the combination vaccine is that it reduces the number of injections required for the immunization of mandatory vaccines in children. Technological advancement in the development of combination vaccines and its ability to prevent interaction between different antigens and enhanced stability drives the market growth.

Hospitals are currently representing the largest market share in the end-user segment in the Haemophilus influenza type b vaccines market. Rising public health awareness regarding the fatality associate with the Hib bacterium such as pneumonia, meningitis, cellulitis, etc. determines the effective immunization of children in the hospitals. Specialty clinics are gathering huge market traction due to proactive initiatives undertaken by government healthcare agencies to provide medical assistance to people residing in remote locations.

North America is presently dominating the geography segment for the Haemophilus influenza type b vaccines market. The rising prevalence of meningitis infection primarily drives market growth in the region. Existence of developed healthcare infrastructure and stringent implementation of the immunization guidelines devised by the USFDA further propel the market growth in the region. Europe is the second-largest regional segment on account of the domicile of key players in the region such as Merck KGaA, Sanofi SA, GlaxoSmithKline, Plc. etc. Furthermore, the supportive regulatory environment provided by the European Medical Agency (EMA) for vaccine distribution determines the market growth in the region. The Asia Pacific is anticipated to be the fastest-growing regional segment during the forecast period owing to the developing healthcare infrastructure and the emergence of local players engaged in the production and sale of Haemophilus influenza type b vaccines.

Select License Type

$4,600
$6,600
$13,200

Safe and Secure SSL Encrypted

Have a Question?

We will help you find what you are looking for.

Call 1-518-730-1560

Contact sales

How can we help you?

Get in touch with us or find an office closest to you.